Bladder Cancer Symptoms, Stages and Treatment
In this article
What Are Bladder and Urothelial Cancer?
Bladder cancer arises from specialised cells lining the urinary tract (urothelium). Because this cell type is also found in the renal pelvis and ureters (upper urinary tract), cancers in these areas are considered together under the common name "urothelial cancer". The past few years have seen an unprecedented succession of new FDA approvals in bladder/urothelial cancer treatment — approaches such as antibody-drug conjugates, targeted treatments and gene therapy have fundamentally changed long-standing treatment standards, particularly in metastatic disease. This guide discusses all stages from early (non-muscle-invasive) to advanced (metastatic) disease and the latest treatment approaches in detail.
Perhaps the most critical concept in bladder cancer is whether the tumour invades the bladder wall's muscle layer (muscularis propria/detrusor muscle) . This single distinction determines classification as "non-muscle-invasive" (NMIBC) or "muscle-invasive" (MIBC), completely changing treatment — therefore, the staging and treatment sections of this guide are structured around it.
Bladder and Upper Urinary Tract Anatomy
The bladder wall consists of the following layers from inside out: urothelium (multilayered transitional epithelium specific to the urinary tract), lamina propria (a thin connective tissue layer), muscularis propria (detrusor muscle — the thick muscle layer enabling bladder emptying), and outermost, perivesical fatty tissue. The renal pelvis and ureters have the same urothelial lining, but much thinner walls — thus even a relatively small upper urinary tract tumour may progress faster into surrounding tissues. The vast majority of urothelial cancers (approximately %90-95) develop in the bladder, and the remainder in the renal pelvis or ureter (upper tract urothelial cancer, UTUC).
How Common Is It? (Current Statistics)
According to the International Agency for Research on Cancer's (IARC) "Global cancer statistics 2024" report (Sung H, et al., CA: A Cancer Journal for Clinicians, published 8 July 2026, DOI: 10.3322/caac.70090), 2024 data show approximately 635.264 new bladder cancer cases (ranking 8th in incidence among all cancers) and 227.626 bladder cancer deaths were reported (ranking 13th in mortality). Bladder cancer shows one of the most pronounced sex differences: age-standardised incidence is 9,3 per 100.000 in men versus 2,3 per 100.000 in women — approximately 4 times more common in men. Most cases are concentrated in Asia (~%40) and Europe (~%33).
According to the American Cancer Society's "Cancer Statistics, 2026" report (Siegel RL, et al., CA: A Cancer Journal for Clinicians, published 13 January 2026, DOI: 10.3322/caac.70043), in 2026 approximately 84.530 new bladder cancer cases (64.730 men, 19.800 women — male/female ratio ~3,3/1) and 17.870 deaths are expected. Lifetime risk is approximately 1 in 125 in men and 1 in 333 in women. Stage-specific 5-year relative survival (SEER 2015-2021 diagnosis cohort): %98 for in situ disease, %73 for localised disease, %41 for regional spread and %9 for distant metastasis; all stages combined, %79 — this wide range clearly shows why early diagnosis is so critical in bladder cancer.
According to the GLOBOCAN 2024 country profile for Türkiye, approximately 13.771 new bladder cancer cases annually are reported, placing bladder cancer 6th among all cancers; with 5.539 deaths, it also ranks 6th in mortality. Most cases (11.963, or %8,9 of male cancers) occur in men, reflecting pronounced male predominance consistent with the global pattern.
Risk Factors
According to a comprehensive meta-analysis including 89 observational studies (van Osch FHM, et al., International Journal of Epidemiology, 2016), compared with never-smokers, current smokers have approximately 3,14-fold higher bladder cancer risk (pooled OR), and former smokers approximately 1,83-fold higher risk. In Europe, the attributable proportion of bladder cancer cases is estimated at approximately %43-50 in men and %26-35 in women — smoking is the largest preventable cause that alone can account for a substantial share of all bladder cancer cases.
- Smoking and tobacco use (the most important risk factor)
- Occupational exposure: aromatic amines in dye, rubber, leather and textile industries
- Chronic Schistosoma haematobium infection (particularly associated with squamous cell carcinoma)
- Long-term chronic urinary catheter use
- History of cyclophosphamide treatment
- History of pelvic radiotherapy
- High arsenic exposure in drinking water
- Lynch syndrome (particularly associated with upper tract urothelial cancer)
- Increasing age and male sex
Chronic urinary schistosomiasis, endemic in parts of Africa and the Middle East, causes chronic bladder wall inflammation, egg accumulation and nitrosamine formation and is particularly associated with squamous cell carcinoma rather than urothelial carcinoma. Although Türkiye is not endemic in this respect, chronic urinary tract inflammation and long-term catheter use may similarly increase squamous cell carcinoma risk through chronic irritation.
Histological Types
| Histological Type | Approximate Frequency | Note |
|---|---|---|
| Urothelial (transitional cell) carcinoma | >%90 | The predominant histological type |
| Squamous cell carcinoma | ~%8 | Associated with chronic irritation/schistosomiasis |
| Adenocarcinoma | ~%2 | Associated with urachal remnants and bladder exstrophy |
WHO-defined urothelial carcinoma subtypes such as micropapillary, plasmacytoid, sarcomatoid, "nested" and small-cell types ("variant histology") are more aggressive subclasses of urothelial carcinoma rather than separate diseases. These variants are more prone to understaging because occult muscle invasion or lymphovascular spread is more likely even in an apparently non-muscle-invasive tumour; therefore, earlier/more aggressive treatment (such as immediate radical cystectomy) may be considered when detected, even if the disease appears early-stage.
Molecular Subtypes and Biomarker Tests
At a molecular level, urothelial carcinoma also separates into at least two broad biological behaviour groups: luminal subtype (generally better prognosis, more frequently associated with FGFR3 alterations) and basal subtype (generally more aggressive, but potentially a relatively higher response to systemic chemotherapy). Although not yet requested as a standard routine clinical test, this classification is increasingly used in research to predict treatment response.
FGFR2/3 gene alterations: present in approximately %15-20 of metastatic urothelial cancers (at even higher rates in upper urinary tract tumours), determining erdafitinib eligibility; generally assessed through a molecular panel from tissue or blood (ctDNA). PD-L1 expression: may inform some immunotherapy decisions (particularly selection of single-agent immunotherapy for chemotherapy-ineligible patients), but approval of EV+pembrolizumab is independent of PD-L1 status. HER2 status: a biomarker used to develop HER2-targeted treatments such as disitamab vedotin (currently approved only in China); it does not yet routinely determine treatment in the US/Europe, but its research importance is increasing.
Symptoms
- Painless visible blood in urine (gross haematuria) — the most common and important symptom
- Frequent urination
- Sudden, compelling urge to urinate (urgency)
- Burning/pain during urination (dysuria)
- Lower back/flank pain (particularly with upper urinary tract involvement, due to ureteral obstruction)
- In advanced disease: pelvic pain, loss of appetite, weight loss, leg swelling
Painless blood in urine is bladder cancer's most typical and common first symptom; absence of pain often misleads patients and delays seeking care, so any episode of blood in urine, even a single one, must be reported to a physician. Irritative symptoms such as frequent urination, urgency and burning are less common and generally associated with carcinoma in situ (CIS) or more invasive disease.
Bleeding is not always visible (gross); microscopic haematuria found incidentally on urinalysis also requires assessment. Under AUA/SUFU's 2020 microhaematuria guideline, patients are classified as low, intermediate or high risk based on factors such as age, smoking history, haematuria degree and occupational exposure; cystoscopy and upper urinary tract imaging are recommended at intermediate and high risk, while more limited evaluation or repeat testing may suffice at low risk.
How Is It Diagnosed?
Cystoscopy, Cytology and Imaging
Cystoscopy (direct bladder visualisation with a thin camera) is the gold standard for detecting a bladder tumour. Urine cytology (microscopic examination of urine cells) is particularly useful for detecting high-grade tumours and CIS, but has limited sensitivity in low-grade tumours. Multiphasic CT urography is the preferred imaging method for assessing both the bladder and upper urinary tract (renal pelvis, ureters).
In addition to standard white-light cystoscopy, "photodynamic diagnosis", in which hexaminolevulinate is instilled into the bladder and examined under special blue light, improves detection of flat, difficult-to-see CIS lesions because the substance accumulates in tumour cells and fluoresces. A meta-analysis of individual patient data (Burger M, et al., European Urology, 2013) showed that this method improves tumour detection and reduces recurrence.
Transurethral resection of bladder tumour (TURBT)is a key procedure providing definitive diagnosis (histology, grade, stage) and initial treatment (visible tumour removal) in bladder cancer. Presence of detrusor (muscle) tissue in the resection specimen is critical for assessing whether the tumour has reached the muscle layer — a specimen without muscle makes staging unreliable and generally requires repeat resection.
Diagnostic Differences in Upper Tract Urothelial Cancer
Because standard cystoscopy cannot visualise the upper urinary tract (renal pelvis, ureter), diagnosis of tumours here relies more decisively on ureteroscopic biopsy and selective (upper urinary tract) urine cytology ; CT urography also remains central to diagnosis. The literature debates a theoretical risk of tumour cell seeding and upstaging from diagnostic ureteroscopy.
Staging: TNM System (AJCC Edition 8)
The most critical distinction in bladder cancer staging is whether the tumour has reached the bladder wall's muscle layer (muscularis propria) . Ta, Tis (CIS) and T1 tumours are classified as "non-muscle-invasive bladder cancer" (NMIBC) ; T2 and above are called "muscle-invasive bladder cancer" (MIBC) — this distinction marks the boundary at which treatment changes completely.
T Category
| T Category | Definition | Group |
|---|---|---|
| Ta | Noninvasive papillary carcinoma (mucosa only, no lamina propria invasion) | Non-Muscle-Invasive (NMIBC) |
| Tis (CIS) | Flat, noninvasive carcinoma in situ | |
| T1 | Lamina propria (subepithelial connective tissue) invasion, without reaching the muscle layer | |
| T2a | Superficial muscle layer invasion (inner half of muscularis propria) | Muscle-Invasive (MIBC) |
| T2b | Deep muscle layer invasion (outer half of muscularis propria) | |
| T3a / T3b | Microscopic / macroscopic (mass-forming) perivesical tissue invasion | |
| T4a | Invasion of prostate stroma, seminal vesicle, uterus or vagina | |
| T4b | Pelvic or abdominal wall invasion |
N and M Categories
N0: no regional lymph node involvement. N1: a single lymph node in the true pelvis (hypogastric, obturator, external iliac or presacral). N2: multiple lymph nodes in the true pelvis. N3: common iliac lymph node involvement. M0: no distant metastasis. M1a: distant metastasis limited to lymph nodes beyond common iliac nodes. M1b: non-lymph-node distant metastasis (such as bone, liver or lung).
Stage Groups
| Stage | TNM |
|---|---|
| 0a | Ta, N0, M0 |
| 0is | Tis, N0, M0 |
| I | T1, N0, M0 |
| II | T2a/T2b, N0, M0 |
| IIIA | T3a-T4a, N0, M0; or T1-T4a, N1, M0 |
| IIIB | T1-T4a, N2/N3, M0 |
| IVA | T4b, any N, M0; or any T, any N, M1a |
| IVB | Any T, any N, M1b |
Risk Classification in Non-Muscle-Invasive Bladder Cancer (NMIBC)
Under the European Association of Urology's (EAU) 2024 update, NMIBC patients are divided into four groups by recurrence and progression risk; this determines who needs surveillance alone, intravesical chemotherapy or BCG:
| Risk Group | General Definition |
|---|---|
| Low risk | First diagnosis, single, Ta, low-grade, <3cm, no CIS, age ≤70 |
| Intermediate risk | Tumours without CIS that do not meet low- or high/very-high-risk criteria |
| High risk | All high-grade T1 tumours; all CIS; some Ta/T1 tumours with additional risk factors (age>70, multiple tumours, size>3cm) |
| Very high risk | High-grade T1/CIS combination + additional risk factors |
Treatment of Non-Muscle-Invasive Bladder Cancer (NMIBC)
Single-Dose Intravesical Chemotherapy After TURBT
Single-dose intravesical chemotherapy (usually mitomycin C) within 24 hours after TURBT reduces recurrence. According to a network meta-analysis of 13 randomised studies (Perlis N, et al., Oncotarget, 2016), mitomycin C significantly reduced recurrence risk (HR 0,44); benefit is particularly evident in low-risk, newly diagnosed Ta tumours, and it must not be given if bladder perforation is suspected.
Repeat TURBT within 2-6 weeks is recommended for all patients with incomplete initial resection, no detrusor (muscle) tissue in the specimen, or high-grade T1 tumours. Residual tumour is found in a substantial proportion (approximately %50-56), and approximately %5-10 of clinical T1 cases are upstaged to muscle-invasive (T2) disease — an important finding showing that initial assessment can understate disease stage.
Intravesical BCG Treatment
Standard treatment for high-risk NMIBC is intravesical immunotherapy derived from attenuated tuberculosis bacilli (Bacillus Calmette-Guérin, BCG). The standard regimen based on SWOG-8507 (Lamm DL, et al., Journal of Urology, 2000) consists of 6-week induction, followed by 3-week courses at months 3 and 6, then maintenance every 6 months for 3 years. In this study, 5-year recurrence-free survival was %60 with maintenance BCG versus %41 with induction alone (p<0,0001) — however, only approximately %16 completed the full 3-year maintenance regimen because of toxicity.
A persistent global BCG shortage has existed since Sanofi stopped producing the Connaught BCG strain in 2012; the sole major manufacturer's new capacity-expansion facility is not expected to be completed before the end of 2026. Clinical adaptations include dose reduction (1/3 - 1/2 of the full dose), prioritisation of high-risk patients (CIS, high-grade tumours), and replacing BCG with intravesical chemotherapy (such as mitomycin or gemcitabine) in low-risk patients.
Under the FDA's 2018 guidance, "BCG-unresponsive" disease must meet at least one criterion: (1) persistent or recurrent CIS within 12 months after adequate BCG; (2) recurrent high-grade Ta/T1 disease within 6 months after adequate BCG; (3) high-grade T1 disease at the first evaluation after induction BCG. "Adequate BCG" means at least 5 of 6 induction doses + at least 2 of 3 maintenance doses (or 5 of 6 induction doses + at least 2 doses of a second induction course).
Newly Approved Treatments in BCG-Unresponsive Disease
Four new treatments have received FDA approval in succession in recent years for BCG-unresponsive patients unwilling or unable to undergo cystectomy — one of the field's fastest periods of development:
| Treatment | FDA Approval | Study | Complete Response Rate | Response Duration |
|---|---|---|---|---|
| Nadofaragene firadenovec (Adstiladrin) — gene therapy | 16 December 2022 | CS-003 (CIS cohort) | %51,2 | Median 9,7 months |
| Pembrolizumab (Keytruda) | 8 January 2020 | KEYNOTE-057 (CIS cohort) | %41 | Median 16,2 months |
| Nogapendekin alfa inbakicept + BCG (Anktiva) | 22 April 2024 | QUILT-3.032 (CIS cohort) | %71,0 | Median 26,6 months |
| TAR-200 (intravesical gemcitabine-releasing system, Inlexzo) | 9 September 2025 | SunRISe-1 | %82 | %51 of responders maintained response for ≥1 year |
Note: Oportuzumab monatox (Vicineum) has not received FDA approval (it received a Complete Response Letter in 2021); it is not an approved US option.
In BCG-unresponsive high-risk disease, radical cystectomy (complete bladder removal) remains the guideline-recommended standard with the most mature long-term oncological data, as an alternative to the bladder-preserving options above. A comparative study (Taylor J, et al., BJU International, 2025) found no significant overall survival difference at medium-term follow-up between bladder-preserving treatment and upfront cystectomy, but reported high-grade recurrence of %37 at month 12 and %52 at month 24, and muscle-invasive progression rising from %7 to %13 with bladder preservation — an observational, nonrandomised study highlighting the importance of not postponing cystectomy indefinitely.
Follow-Up After NMIBC Treatment: Why Is Lifelong Surveillance Needed?
One of bladder cancer's most distinctive features is its very high tendency to recur after treatment, which may persist for years — therefore regular cystoscopic follow-up continues for many years after NMIBC treatment (lifelong at many centres). Frequency depends on risk: less often at low risk (for example, annually after the first year), and much more frequently at high or very high risk, particularly during the first 1-2 years (for example, every 3 months), with urine cytology and upper urinary tract imaging when needed. This intensive schedule aims to detect recurrence early and recognise possible progression (muscle invasion) promptly.
Treatment of Muscle-Invasive Bladder Cancer (MIBC)
Neoadjuvant chemotherapy before radical cystectomy is standard for patients eligible for cisplatin (appropriate renal function, hearing and performance status). According to SWOG-8710/INT-0080 (Grossman HB, et al., NEJM, 2003), bladder cancer death risk was significantly lower with neoadjuvant chemotherapy+cystectomy than cystectomy alone (HR 0,60; p=0,002) — benefit arises almost entirely from cisplatin-containing regimens, so neoadjuvant chemotherapy has no proven benefit in cisplatin-ineligible patients (cisplatin eligibility is often assessed using "Galsky criteria", based on renal function, performance status, hearing loss, peripheral neuropathy and heart failure — carboplatin-based regimens are generally preferred in ineligible patients). Regarding regimen selection, VESPER's neoadjuvant subgroup analysis reported superior 5-year overall survival with dose-dense MVAC (dd-MVAC) versus gemcitabine+cisplatin (GC) (%66 versus %57, HR 0,71) — direct randomised evidence comparing the regimens.
Radical cystectomy (removing the bladder, surrounding organs and pelvic lymph nodes) is standard curative surgery in MIBC. In appropriately selected patients (single tumour, no hydronephrosis, no extensive CIS, complete TURBT possible, able to tolerate chemoradiotherapy), bladder-preserving trimodality treatment consisting of TURBT+chemoradiotherapy is an alternative curative option. According to a pooled analysis of RTOG protocols (8802-9906) (Mak RH, et al., JCO, 2014), this approach yielded 5/10-year overall survival of %57/%36 and disease-specific survival of %71/%65; %21 subsequently required salvage cystectomy.
Adjuvant nivolumab is standard for high-risk patients after radical cystectomy, regardless of PD-L1 status or previous neoadjuvant treatment. FDA approval: 20 August 2021. Updated 5-year data show disease-free survival of 21,9 versus 11,0 months overall (HR 0,74), with a much greater difference in the PD-L1≥%1 subgroup (55,5 versus 8,4 months, HR 0,58). Overall survival data have also matured: 75 versus 50,1 months overall (HR 0,83); in the PD-L1≥%1 subgroup, median survival was not reached, versus 59,4 months in the control arm (HR 0,63) — benefit is substantially greater in PD-L1-positive tumours, but FDA approval is not restricted by PD-L1 status.
On 28 March 2025, the FDA approved perioperative durvalumab with neoadjuvant gemcitabine+cisplatin followed by single-agent durvalumab maintenance after cystectomy in cisplatin-eligible MIBC. NIAGARA showed significantly improved event-free survival (HR 0,68; 2-year rate %67,8 versus %59,8) and overall survival benefit (HR 0,75; 2-year rate %82,2 versus %75,2), regardless of pathological complete response. This is a truly new and current approval added to the MIBC treatment paradigm.
Treatment in Metastatic Urothelial Cancer
Over the past three years, metastatic urothelial cancer treatment has seen probably one of the fastest changes in standards in all solid tumour oncology. The first-line platinum-based chemotherapy standard, unchanged for decades, gave way to a completely different approach in 2023.
Enfortumab vedotin, a Nectin-4-targeting antibody-drug conjugate, combined with pembrolizumab received FDA approval on 15 December 2023 and became the new first-line standard replacing platinum-based chemotherapy in metastatic urothelial cancer. EV-302 showed striking results versus standard chemotherapy: progression-free survival 12,5 versus 6,3 months (HR 0,450); overall survival 31,5 versus 16,1 months (HR 0,468) — nearly doubling median overall survival, one of the largest absolute survival differences reported in current gynaecological and urological oncology. These results ended platinum-based chemotherapy's decades-long first-line standard status. A practical advantage is that the combination can be given regardless of cisplatin eligibility — previously, cisplatin eligibility determined treatment choice from the outset in the chemotherapy-first approach.
Enfortumab vedotin first received accelerated approval in 2019 (single-arm EV-201), then standard approval on 9 July 2021 based on EV-301 (overall survival 12,9 versus 9,0 months, HR 0,70, in patients progressing after platinum/immunotherapy). Since EV+pembrolizumab became the first-line standard, the role of single-agent enfortumab vedotin has narrowed substantially; it is now mainly considered for patients progressing after first-line chemotherapy (for example, carboplatin in cisplatin-ineligible patients) or unable to tolerate EV+pembrolizumab.
Avelumab maintenance, approved on 30 June 2020, significantly prolonged overall survival in patients without progression after first-line platinum-based chemotherapy (21,4 versus 14,3 months, HR 0,69). Since EV+pembrolizumab became the first-line standard, avelumab maintenance continues mainly in patients started on chemotherapy (for example, with a contraindication to EV+pembrolizumab or who do not prefer it); no randomised study directly compares these approaches yet.
Approximately %15-20 of metastatic urothelial cancers (more in upper tract urothelial cancer) carry FGFR2/3 alterations, and these patients may benefit from the oral FGFR inhibitor erdafitinib. It received accelerated approval in 2019, converted to full approval on 19 January 2024 based on THOR: overall survival was 12,1 versus 7,8 months compared with chemotherapy in FGFR2/3-altered patients previously treated with immunotherapy. Full approval narrowed the label — some FGFR2 fusion subgroups and patients without prior PD-1/L1 treatment/ineligible for it were excluded.
Sacituzumab govitecan (Trodelvy), granted accelerated approval in 2021 based on TROPHY-U-01, had its US urothelial cancer indication voluntarily withdrawn by the manufacturer after the confirmatory phase 3 study TROPiCS-04 failed its primary overall survival endpoint ; the withdrawal took place on 18 October 2024. This is an important current example of how accelerated approval operates when a confirmatory trial fails; this drug is no longer an approved treatment for metastatic urothelial cancer in the US.
Disitamab vedotin, a HER2-targeted antibody-drug conjugate, is approved in China (NMPA) for HER2-positive urothelial cancer, but not in the US (FDA) or Europe (EMA) as of this article's preparation date.
As the new first-line standard (EV+pembrolizumab) becomes widespread, options after progression on it are being reshaped: platinum-based chemotherapy if not previously used, erdafitinib for FGFR2/3 alterations, or clinical trial participation are leading choices. Withdrawal of sacituzumab govitecan removed another option; checking current NCCN/ESMO guidelines is important in this rapidly changing field.
Special Considerations in Upper Tract Urothelial Cancer (UTUC)
According to Ju JY and colleagues' study (American Journal of Surgical Pathology, 2018), approximately %1-3 of upper tract urothelial cancers may be associated with Lynch syndrome; MMR protein loss was found in %9 of their cohort. The authors recommend, regardless of age, routine MMR immunohistochemistry screening in all UTUC patients — UTUC may be Lynch syndrome's first presenting (sentinel) cancer, and screening based only on age limits may miss important cases. This differs from the more selective Amsterdam/Bethesda-based screening approaches in some other guidelines, and practice may vary between guidelines.
Diagnostic differences (ureteroscopy, selective cytology) are discussed above. Standard treatment in localised disease is radical nephroureterectomy (removing the kidney, ureter and bladder cuff together); kidney-sparing endoscopic treatment may also be considered for selected small, low-risk, low-grade tumours. Metastatic UTUC is treated largely similarly to bladder-origin urothelial cancer.
Treatment-Related Side Effects and Management
Intravesical BCG and Chemotherapy
The commonest BCG adverse effects are burning during urination, frequency and mild fever; disseminated systemic BCG infection is rare but requires urgent medical assessment. Intravesical chemotherapy (mitomycin, gemcitabine) generally causes local bladder irritation, with fewer systemic adverse effects than intravenous chemotherapy.
Systemic Chemotherapy
Cisplatin-based regimens can cause renal toxicity, hearing loss, peripheral neuropathy and bone marrow suppression; careful pretreatment assessment of renal function, hearing and performance status (cisplatin eligibility) is therefore important.
Enfortumab Vedotin
Associated with peripheral neuropathy, rash (sometimes severe; rare serious reactions such as Stevens-Johnson syndrome have been reported) and hyperglycaemia; skin reactions should be recognised and reported early.
Pembrolizumab and Other Immunotherapies
Checkpoint inhibitors carry a risk of "immune-related adverse effects" from excessive immune activation (colitis, hepatitis, pneumonitis, endocrine disorders); management ranges from monitoring to corticosteroids depending on severity.
Erdafitinib
Associated with central serous retinopathy (an eye complication potentially impairing vision, requiring regular eye examinations) and hyperphosphataemia (increased blood phosphorus), specific to FGFR inhibition; hand-foot syndrome and dry mouth may also occur.
Urinary Diversion and Quality of Life After Radical Cystectomy
After bladder removal, urinary diversion is required to eliminate urine (a urine bag/stoma, or creation of a new bladder — "neobladder" — from a bowel segment); selection depends on age, renal function and preference. Detailed preoperative information and postoperative stoma/urinary care education are crucial to quality of life.
A Special Situation: Treatment in Older Patients
Bladder cancer predominantly affects older people, with median diagnosis age in the 70s, directly influencing treatment decisions. Functional status (performance score), renal function, hearing and comorbidities matter more than chronological age — largely explaining the importance of the cisplatin eligibility assessment above. For radical cystectomy in frail patients, surgical risks must be weighed carefully against bladder-preserving approaches such as trimodality treatment; geriatric assessment may help treatment planning in suitable patients.
FDA Approval Timeline: A Revolution in Bladder and Urothelial Cancer Treatment
Intravesical BCG One of the First Cancer Immunotherapy Approvals
FDA-approved as standard treatment in high-risk NMIBC; one of the oldest and longest-used examples of cancer immunotherapy.
Atezolizumab
The first checkpoint inhibitor approved in metastatic urothelial cancer progressing after platinum.
Nivolumab, Durvalumab, Avelumab, Pembrolizumab
Four additional checkpoint inhibitors were soon approved in post-platinum metastatic urothelial cancer.
Enfortumab Vedotin The First Nectin-4 ADC
Accelerated approval based on EV-201; the first Nectin-4-targeted antibody-drug conjugate approved in any cancer.
Pembrolizumab (BCG-Unresponsive CIS)
Approved in BCG-unresponsive high-risk NMIBC based on KEYNOTE-057.
Avelumab Maintenance Among the First Maintenance Immunotherapy Approvals
Approved as maintenance after first-line chemotherapy based on JAVELIN Bladder 100.
Enfortumab Vedotin (Full Approval)
Converted to standard approval based on EV-301.
Adjuvant Nivolumab
Approved in high-risk patients after radical cystectomy based on CheckMate 274.
Nadofaragene Firadenovec The First Approved Gene Therapy
The first gene therapy approved in BCG-unresponsive NMIBC, based on CS-003.
Enfortumab Vedotin + Pembrolizumab The New First-Line Standard
Based on EV-302/KEYNOTE-A39, replaced decades of platinum-based chemotherapy as standard; striking results nearly doubled overall survival.
Erdafitinib (Full Approval)
Converted to standard approval in FGFR2/3-altered patients based on THOR.
Nogapendekin Alfa Inbakicept (Anktiva) + BCG
Approved in BCG-unresponsive CIS based on QUILT-3.032.
Withdrawal of Sacituzumab Govitecan's Indication
The manufacturer voluntarily withdrew the urothelial cancer indication after the confirmatory TROPiCS-04 study failed.
Perioperative Durvalumab (NIAGARA)
Neoadjuvant+adjuvant durvalumab approved in cisplatin-eligible MIBC; established a new MIBC treatment standard.
TAR-200 (Inlexzo) The First Intravesical Release System
Approved in BCG-unresponsive CIS based on SunRISe-1; represents a new administration method providing prolonged drug release within the bladder.
Diagnosis, Licensing and Reimbursement in Türkiye
Intravesical BCG, mitomycin C, gemcitabine, cisplatin-based regimens and radical cystectomy/nephroureterectomy are widely used and covered by SGK in Türkiye. This research could not verify Türkiye-specific effects of the global BCG shortage; confirming current supply with your treatment centre is recommended.
According to our sources, nivolumab is currently covered by SGK for melanoma, non-small cell lung cancer, classical Hodgkin lymphoma and renal cell cancer, while the adjuvant bladder cancer indication is absent from this list — coverage for this specific use is therefore uncertain and unverified. The immunotherapy expansions in the SUT update of 10 July 2025 also appear not to explicitly include bladder/urothelial cancer. For enfortumab vedotin, avelumab, erdafitinib and durvalumab, current TİTCK licensing and SGK reimbursement for urothelial cancer could not be clearly verified in this research.
Although sacituzumab govitecan is known to be licensed in Türkiye, this research could not verify which cancer types its licensed indication covers. Its US urothelial cancer indication was withdrawn in October 2024 (discussed above); directly confirming current Turkish licensing with your physician or through the TİTCK Summary of Product Characteristics (KÜB) is therefore important.
This research could not verify Turkish licensing/reimbursement for very recently approved treatments such as nadofaragene firadenovec (Adstiladrin), nogapendekin alfa inbakicept (Anktiva) and TAR-200 (Inlexzo), because of their recent approvals; checking TİTCK and SGK's official sources directly is recommended.
Frequently Asked Questions
- Does blood in urine always mean cancer?
- No, it may have many benign causes such as urinary tract infection or stones. However, painless blood in urine in particular must be assessed by a urologist because it is bladder cancer's most common first symptom.
- Why is the NMIBC–MIBC distinction so important?
- Whether the tumour has reached the muscle layer fundamentally determines whether treatment preserves the bladder (such as TURBT+BCG) or is more aggressive (radical cystectomy, systemic treatment).
- Is cystectomy still the only option in BCG-unresponsive disease?
- No. Recently approved bladder-preserving options such as nadofaragene firadenovec, pembrolizumab, nogapendekin alfa inbakicept and TAR-200 offer alternatives for patients unwilling or unable to undergo cystectomy.
- Is chemotherapy no longer used in metastatic bladder cancer?
- Chemotherapy remains important, but the superior first-line results of enfortumab vedotin+pembrolizumab mean it is no longer the first choice for most patients; it is still used in particular circumstances, such as contraindication to this combination.
- Is upper urinary tract cancer (renal pelvis/ureter) the same as bladder cancer?
- It arises from the same cell type (urothelium), with largely similar treatment principles, but diagnostic methods differ and Lynch syndrome screening is particularly important in upper urinary tract tumours.
- Sung H, et al. "Global cancer statistics 2024." CA: A Cancer Journal for Clinicians, 2026. DOI: 10.3322/caac.70090
- IARC Global Cancer Observatory (GLOBOCAN 2024) — Bladder Cancer and Türkiye Country Fact Sheet. gco.iarc.who.int
- Siegel RL, et al. "Cancer Statistics, 2026." CA: A Cancer Journal for Clinicians, 2026. DOI: 10.3322/caac.70043
- van Osch FHM, et al. Smoking and bladder cancer risk, meta-analysis. International Journal of Epidemiology, 2016.
- Ju JY, et al. "Universal Lynch Syndrome Screening in Upper Tract Urothelial Carcinoma." American Journal of Surgical Pathology, 2018.
- Burger M, et al. Hexaminolevulinate blue-light cystoscopy, meta-analysis. European Urology, 2013.
- Perlis N, et al. Single-dose intravesical chemotherapy after TURBT, network meta-analysis. Oncotarget, 2016.
- Lamm DL, et al. SWOG-8507, BCG maintenance regimen. Journal of Urology, 2000.
- FDA. "BCG-Unresponsive Nonmuscle Invasive Bladder Cancer" guidance, 2018.
- FDA approval announcement: Nadofaragene firadenovec (Adstiladrin), CS-003 study, 16 December 2022.
- FDA approval announcement: Pembrolizumab, KEYNOTE-057, 8 January 2020.
- FDA approval announcement: Nogapendekin alfa inbakicept (Anktiva) + BCG, QUILT-3.032, 22 April 2024.
- FDA approval announcement: TAR-200 (Inlexzo), SunRISe-1, 9 September 2025.
- Grossman HB, et al. SWOG-8710/INT-0080, neoadjuvant chemotherapy. NEJM, 2003.
- VESPER study, dd-MVAC vs gemcitabine+cisplatin, neoadjuvant subgroup analysis. Lancet Oncology, 2021-2022.
- Mak RH, et al. RTOG pooled analysis, bladder-preserving trimodality treatment. Journal of Clinical Oncology, 2014.
- Bajorin DF, et al. CheckMate 274, adjuvant nivolumab. NEJM, 2021; 5-year update 2024-2025.
- Powles T, et al. NIAGARA, perioperative durvalumab. NEJM, 2024; FDA approval 28 March 2025.
- Powles T, et al. EV-302/KEYNOTE-A39, enfortumab vedotin+pembrolizumab. NEJM, 2024; FDA approval 15 December 2023.
- Powles T, et al. EV-301, enfortumab vedotin full approval. NEJM, 2021; FDA approval 9 July 2021.
- Powles T, et al. JAVELIN Bladder 100, avelumab maintenance. NEJM, 2020; FDA approval 30 June 2020.
- Loriot Y, et al. THOR, erdafitinib full approval. NEJM, 2023; FDA approval 19 January 2024.
- Gilead Sciences. Announcement withdrawing sacituzumab govitecan's urothelial cancer indication, 18 October 2024.
- Communiqué Amending the Healthcare Implementation Communiqué, 10 July 2025 (SGK SUT update).
Was this article helpful?
Your feedback helps us improve our content.
